Kazia Therapeutics Ltd (NASDAQ:KZIA) is an innovative oncology-focused biotechnology company based in Sydney.
The company’s product pipeline includes two clinical-stage drug development candidates and Kazia is also working to develop therapies across a range of oncology indications.
Kazia’s lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K/AK/mTOR pathway, which is being developed to treat glioblastoma, the most common and aggressive form of primary brain cancer in adults.
